Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBOLD-Asia: Phase 3 study of AZD5004 in Asian adults with obesity or overweight with or without type 2 diabetes mellitus
CTR20263029Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elecoglipron in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Aug 2026; status: active.
02
Drugs
elecoglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263029.